Do the latest five targeted drugs for cholangiocarcinoma include pemetinib/pemetinib?

Targeted drug therapy for cholangiocarcinoma (CCA) is an evolving field, with new research and drugs emerging. However, there is currently no fixed definition of the "top five latest targeted drugs" because the suitability and efficacy of drugs may vary depending on individual differences, tumor characteristics and clinical trial results. FGFR inhibitors are usually ATP competitive reversible inhibitors (such as erdafitinib[erdafitinib], infigratinib[Infitinib], pemetinib and derazantinib).

Pemigatinib/Pemigatinib (Pemigatinib) was obtained in April 2020The U.S. Food and Drug Administration (FDA)approved, becoming the first cholangiocarcinoma's targeted therapeutic drugs. This isIt follows the FIGHT-202 trial, a phase 2 multicenter clinical trial spanning North America, Europe and Asia, in patients with advanced/metastatic or surgically unresectable FGFR2 translocations who have failed prior treatmentcholangiocarcinomaThe objective response rate among patients was 35.5% (3 cases of complete response and 35 cases of partial response). The median duration of response was 9.1 months. The majority (64%) of patients experienced grade 3 or worse adverse events, with the most common adverse event being hypophosphatemia. More serious side effects include cholangitis and pleural effusion, but no treatment-related deaths have been reported.

However, the treatment of cholangiocarcinoma is usually individualized and requires comprehensive consideration of multiple factors, including the genetic mutation of the tumor, the patient's overall health, and previous treatment history. In addition to pemetinib, there are other targeted drugs and treatment strategies being studied and applied, such as targeted drugs for IDH1/2 mutations, VEGF (vascular endothelial growth factor) inhibitors, etc. These drugs can target different pathological characteristics and molecular mechanisms of cholangiocarcinoma to improve treatment effects and patient survival. When choosing targeted drug treatment, doctors will conduct genetic testing and evaluation based on the patient's specific situation to determine the most suitable treatment plan. In addition, clinical trials are also an important way to evaluate new drugs and treatments. Patients can consider participating in relevant clinical trials to obtain the latest treatment opportunities.

It should be noted that the therapeutic effect of targeted drugs is not absolute, and the response of each patient may be different. Moreover, targeted drugs may also be associated with certain side effects. Therefore, during the treatment process, patients should cooperate closely with the doctor and communicate the treatment effects and adverse reactions in a timely manner so that the doctor can make adjustments and management according to the situation. Most importantly, the treatment of cholangiocarcinoma usually requires a combination of multiple treatments, including surgery, radiotherapy, chemotherapy, and targeted therapy. Doctors will develop a personalized treatment plan based on the patient's specific conditions to improve treatment effects and quality of life.